Abstract:Abstract Introduction: The advent of CAR-T cell therapies have significantly improved outcomes of patients with relapsed/refractory B-cell malignancies - particularly those with diffuse large B-cell lymphoma (R/R DLBCL) with chemorefractory disease. However, despite the early promise and improved access, utilization of commercially approved CAR-T treatments has lagged behind early estimates generated by historical outcomes of patients with R/R DLBCL. The influences and challenges that limit utilization of CAR-T treatments and practice-specific treatment patterns in CAR-T-eligible patients have also not been studied systematically. Herein we provide comprehensive comparative characteristics, treatment patterns, and outcomes of patients with R/R DLBCL who would be deemed eligible for CAR-T therapy, per the criteria utilized in pivotal clinical trials performed for commercial approval of these agents. Methods: This retrospective study utilized the COTA real-world database, a de-identified database of RWD derived from the electronic health records of partnered healthcare providers in the United States. A total of 1663 patients treated for DLBCL after 2016 were included in the analysis. Patient and disease outcomes, therapy utilizations and comparative outcomes with respect to clinical trial criteria were extracted and analyzed descriptively. Line of therapy was assigned programmatically utilizing standard definitions and guidelines. Survival and mortality outcomes were assessed by KM method across various subgroups. Results: In the 1663 patients with DLBCL included in this study, the median age was 66 years (IQR: 56-75). 58.9% were males and 73.6% were Caucasians. Practice setting distribution of this cohort was 50.6% academic and 49.4% community. 7.9% of the population (N=131) had primary refractory disease and 45.1% had relapsed disease, including 4.5% (N=75) who relapsed following autologous stem cell transplantation (ASCT). Most common histology was DLBCL not otherwise specified, 31.1% had bulky disease and 69.3% had extranodal disease at initial presentation. Double- or triple-hit status was not assessed in 52.0% of patients. With a median follow up of 1.8 years, the 12-month overall survival (OS) from time of starting first line treatment of the entire cohort was 84%. Patients with primary refractory disease had a median OS of 21.2 months and patients with relapsed disease post ASCT had a median OS of 33 months. We further evaluated the outcomes of 145 patients who underwent CAR-T therapy (8.7% of the entire cohort) and compared outcomes to 169 patients who did not undergo CAR-T therapy despite meeting the eligibility criteria utilized in the pivotal ZUMA-1 or JULIET trial for axicabtagene cilolecleucel and tisagenlecleucel respectively (10.1% of the entire cohort). Patients who did not undergo CAR-T therapy were older (median age 63 vs. 59 years respectively, p=0.031) and almost all in the academic setting (96.4% vs 56.6% respectively, p<0.001). The rest of the demographics and comorbid conditions were similar between the 2 groups. A higher proportion of patients in the group that did not proceed to CAR-T had stage 1-2 disease at diagnosis (27.2% vs 14.5% respectively, p<0.001), ECOG performance status of 0-1 (100% vs 51.0%, p<0.001), normal LDH (52.1% vs. 19.3%, p<0.001). With a median follow up of 3 years, the 12-month OS was 91% in this cohort, and compared favorably for patients undergoing CAR-T for whom the median PFS, 12-month OS, and 12-month NRM was 9.3 months, 94%, and 6.8% respectively at a median follow up of 2.0 years. These patients were treated with various additional therapies the details of which will be presented at the meeting. Conclusions: Our study details the characteristics of a real-world population of patients with DLBCL and evaluates outcomes specifically with respect to CAR-T therapy utilization. Outcomes of patients undergoing CAR-T therapies are similar to previously reported data. While retrospective reviews are limited in their ability to truly assess all patient and physician factors that influence therapeutic selection, our study highlights clinical characteristics of potentially eligible patients who do not undergo CAR-T treatment. Furthermore, it provides an avenue to compare outcomes of novel therapies in the relapsed setting especially when compared to CAR-T treatment and the promising survival outcomes observed presumably due to their use. Disclosures Awan: Verastem: Consultancy; ADCT therapeutics: Consultancy; Incyte: Consultancy; MEI Pharma: Consultancy; Abbvie: Consultancy; Cardinal Health: Consultancy; Merck: Consultancy; BMS: Consultancy; Beigene: Consultancy; Kite pharma: Consultancy; Celgene: Consultancy; Karyopharm: Consultancy; Pharmacyclics: Consultancy; Gilead sciences: Consultancy; Janssen: Consultancy; Johnson and Johnson: Consultancy; Astrazeneca: Consultancy; Dava Oncology: Consultancy; Genentech: Consultancy. Belli: COTA, Inc.: Current Employment, Other: Equity ownership. Hansen: COTA, Inc.: Current Employment. Chung: COTA, Inc.: Current Employment. Wang: COTA, Inc.: Current Employment, Other: Equity ownership.

485. Improved Outcome of COVID-19 in CAR T Cell Treated Patients; results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

2694. Infectious Complications in CAR-T Cell Therapy Recipients: A Systematic Review and Meta-Analysis

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy

Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution

Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T Cell Therapy Recipients with Pre-Cellular Therapy SARS-CoV-2 Infection

PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA

Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy

COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics

Identification of Barriers of CAR-T Utilization in Patients with Diffuse Large B-Cell Lymphoma

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies

Survival Trends in Diffuse Large B-Cell Lymphoma (DLBCL) in the CAR-T Cell Therapy Era Vs Pre-CAR-T Cell Therapy Era in the United States: A Population-Based Study

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Updated efficacy and safety report of a phase I trial of donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.

Safety and efficacy of allogeneic CAR-T cells in B-cell malignancies: A systematic review and meta-analysis.

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Abstract 882: Harnessing single cell multi-omics data to identify predictors of clinical outcome in CD19 CAR T cell therapy